|Dr. Eric M. Ostertag||CEO, Sec. & Director||703.16k||N/A||1973|
|Mr. Kerry D. Ingalls||Chief Operating Officer||384.98k||N/A||1962|
|Dr. Matthew A. Spear||Chief Medical Officer||597.94k||N/A||1967|
|Mr. Mark J. Gergen||Pres, Chief Bus. Officer & Director||N/A||N/A||1963|
|Ms. Johanna M. Mylet CPA||Sr. VP of Fin.||N/A||N/A||1987|
|Mr. Harry J. Leonhardt||Gen. Counsel ,Chief Compliance Officer & Corp. Sec.||N/A||N/A||1957|
|Ms. Kristin Martin||Chief HR Officer||N/A||N/A||N/A|
|Devon Shedlock||Sr. VP of R&D||N/A||N/A||N/A|
|Mr. Jeff Knight||Sr. VP of Global Operations||N/A||N/A||N/A|
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.
Poseida Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.